HDAC2 in HDAC inhibitor-based therapy for CRC

基于 HDAC 抑制剂的 CRC 治疗中的 HDAC2

• 批准号: 8511592
• 负责人: JING HU
• 金额: $ 29.75万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-16 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8511592
• 关键词: APC gene; Adenomatous Polyposis Coli; Antineoplastic Agents; Biological; Biology; Cell Nucleus; Clinical; Clinical Trials; Colon; Colon Carcinoma; Colorectal Cancer; Combined Modality Therapy; Complex; Cutaneous; Cytoplasm; Deacetylase; Development; Disease; Drug Combinations; Event; Future; Genetic; Glycogen (Starch) Synthase; Goals; HDAC2 gene; Histone Acetylation; Histone Deacetylase; Histone Deacetylase Inhibitor; Human; Intestinal Mucosa; Intestinal Polyps; Intestines; Knock-out; Lead; Licensing; Lysine; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Metastatic/Recurrent; Mucous Membrane; Mus; Mutation; Nuclear; Pathway interactions; Patients; Play; Protein Isoforms; Proteolysis; Refractory; Regulation; Resistance; Role; Sampling; Signal Transduction; Small Intestines; Solid Neoplasm; T-Cell Lymphoma; Testing; Therapeutic; Tissues; United States; Up-Regulation; Vorinostat; Work; Xenograft Model; adenoma; base; cancer cell; clinical effect; design; functional loss; in vivo; novel; overexpression; resistance mechanism; tissue culture; tumor; tumor progression; tumor xenograft; tumorigenesis

DESCRIPTION (provided by applicant): Histone deacetylase inhibitors (HDACis) are a promising new class of anticancer drugs. Two HDACis are licensed by the United States FDA for the treatment of advanced cutaneous T-cell lymphoma. Although clinical trials with HDACis as monotherapy in solid tumors have not been successful, HDACi shows promise in combination therapy for patients with recurrent metastatic lung cancer, suggesting that the full therapeutic potential of current HDACis will probably be best realized through a combination with other anticancer agents. However, currently there is little information to direct the clinical use of HDACi in combination with other agents. As colorectal cancer (CRC) remains an essentially incurable disease, it is critical to identify mechanism of HDACi resistance that can lead to combination strategies that increase HDACi therapeutic potential in CRC. The overall goal of this project is to uncover the HDAC mechanism responsible for the limited efficacy of HDACi treatment in colorectal cancer. There are 18 HDACs in humans and these different HDACs are not redundant in their function. In CRC, one of the most cancer relevant HDACs is HDAC2. We have found that in CRC cells, HDAC2 knockdown enhances the anti-tumor effect of SAHA, whereas overexpression of HDAC2 confers resistance to SAHA treatment. These findings strongly suggest that HDAC2 influences HDACi sensitivity and contributes to refractoriness to HDACi therapy in CRC cells. But the underlying mechanism by which HDAC2 works remains undefined. Clinical evidence suggests that HDACi refractoriness may involve mechanisms independent of deacetylase inhibition. Intriguingly, we have discovered that HDAC2 possesses a deacetylase-independent sumoylation-promoting activity and promotes sumoylation of Gsk3¿ (a key component of Wnt signaling). Based on our preliminary results, we hypothesize that HDAC2 sumoylation-promoting activity contributes to HDACi refractoriness in CRC cells by upregulating the Wnt/¿-catenin pathway through enhancing Gsk3¿ sumoylation. In this proposal, we will determine the role of the Wnt/¿-catenin pathway in HDAC2-mediated refractoriness in HDACi therapy. We will then validate the role of HDAC2 sumoylation-promoting activity in HDACi sensitivity of CRC cells. Finally, we will dissect how HDAC2 upregulates the Wnt/¿-catenin pathway through enhancing Gsk3¿ sumoylation. The successful completion of this proposed study could reveal a possible cause of insensitivity to HDACi treatment in CRC.

描述（由申请人提供）：组蛋白去乙酰化酶抑制剂（HDACis）是一类很有前途的新型抗癌药物。两种HDACis被美国FDA批准用于治疗晚期皮肤t细胞淋巴瘤。尽管HDACis作为单一治疗实体肿瘤的临床试验尚未成功，但HDACi在复发性转移性肺癌患者的联合治疗中显示出了希望，这表明目前HDACis的全部治疗潜力可能最好通过与其他抗癌药物的联合治疗来实现。然而，目前指导临床的信息很少